linjc16/ctgov huggingface dataset:
Oral Losartan in Prevention of Post-ERCP Paancreatitis

Study Overview
=================
Brief Summary
-----------------
Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with another 50 patients underwent ERCP without receiving oral losartan.

Official Title
-----------------
Evaluation of Oral Losartan in the Prevention of Post-ERCP Pancreatitis

Conditions
-----------------
Post-ERCP Acute Pancreatitis

Intervention / Treatment
-----------------
* Drug: oral losatan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any adult patient indicated for ERCP Patients with obstructive jaundice. Patients with dilated intra-hepatic or extra-hepatic bile ducts due to malignant or benign lesions. Exclusion Criteria: Patients refusing to undergo the procedure or signing the informed consent Patients with clinically evident acute pancreatitis before the procedure Patients with previous endoscopic or surgical sphincterotomy Patients with current use of losartan Patients who are allergic or hypersensitive to losartan or hydro soluble contrast solutions Patients receiving NSAIDS within a week prior to assessment Patients with severe co-morbid conditions as cardiovascular disease, renal failure or decompensated liver cirrhosis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: patients received the oral losartan<br>50 patients with obstructive jaundice indicated for ERCP and received oral losartan 1 hour before ERCP as a prophylaxis of post-ERCP pancreatitis | Drug: oral losatan<br>* 50 mg of oral losartan one hour before the ERCP once<br>|
| No Intervention: patients didn't receive the oral losartan<br>50 patients with obstructive jaundice indicated for ERCP and didn't receive any prophylactic drugs | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with development of acute pancreatitis | Number of participants with development of abdominal pain and elevated serum amylase and/or lipase | 24 hours |
Effect of Early Mobilization on Regional Lung Ventilation Assessed by EIT

Study Overview
=================
Brief Summary
-----------------
Changes in pulmonary ventilation and perfusion by EIT to out-of-bed activity in critically ill patients

Detailed Description
-----------------
EIT measurements were performed in ICU patients who under out-of-bed activity Measurement of EIT was taken place at 4 time points: supine position before early mobilization, 30min, 60min during early mobilization, supine positon after early mobilization. All of them were without invasive ventilation. Measurements were made in triplicate at all time points.

Official Title
-----------------
Using EIT to Assess the Effect of Early Mobilization on Regional Lung Ventilation in ICU Patients

Conditions
-----------------
Critical Illness, Lung Function Decreased, ICU Acquired Weakness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients was performed out-of-bed activity in the ICU department based on doctor order Age (> 18 years old) and (< 90 years old) Exclusion Criteria: Chest skin is injury and cannot be monitored by EIT The patients or their families refused to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ICU patients with early mobilization<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lung regional ventilation distribution | lung regional ventilation distribution was measured by EIT | Hour 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EIT, early mobilization
Head Position for Endotracheal Intubation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether degree of neck flexion affect on laryngeal view and discomfort during endotracheal intubation in adult patients.

Detailed Description
-----------------
The neck flexion using a 8 to 10 cm head elevation has been suggested to align laryngeal, pharyngeal and oral axes and facilitate endotracheal intubation by direct laryngoscopy. There have been scarce clinical studies about the appropriate degree of neck flexion for endotracheal intubation. In the present study, the laryngeal view and physician's discomfort during endotracheal intubation were evaluated according to the two degrees of neck flexion(4 cm vs 8 cm) using a 4 or 8 cm height of pillows, respectively, in adult patients.

Official Title
-----------------
The Degree of Neck Flexion Does Not Influence on the Laryngeal View and Discomfort During Endotracheal Intubation in Adult Patients

Conditions
-----------------
Intubation; Difficult

Intervention / Treatment
-----------------
* Other: Neck flexion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective operation time ≤2hrs American Society of Anesthesiologist, Physical Status 1 or 2 age ; 18 - 90 years Exclusion Criteria: patient has upper respiratory infection symptoms limited mouth opening teeth problems expecting difficult airway congenital heart disease patient has a possibility of aspiration pneumonia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Degree of neck flextion<br>Two degrees of neck flexion were achieved using a 4 cm or 8 cm height of pillow | Other: Neck flexion<br>* Patient's neck was flexed using a 4 cm or 8 cm height of pillow<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Laryngeal view as index of ease of insertion | Cormack Lehane grade during endotracheal intubation | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Discomfort of anesthesiologist during endotracheal intubation | Anesthesiologist can feel difficulties in mouth opening and in insertion of laryngoscopic blade into oral cavity according to the degrees of neck flexion | one year |
Activity at Ventilation Threshold on Appetite and Food Intake in Boys

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize exercise increases short term appetite and food intake, and interferes with satiety and satiations to a preload in normal weight, overweight and obese boys.

Detailed Description
-----------------
The effect of exercise (EXR) on short-term food intake (FI) and subjective appetite was investigated in normal weight (NW), overweight (OW) and obese (OB) boys were randomized into 4 treatments. Each boy consumed either a non-caloric sweetened control (CON) or GLU drink after either exercise (EXR) or sedentary activity. Subjects exercised at their ventilation threshold (VeT).

Official Title
-----------------
Effect of Activity at the Ventilation Threshold on Appetite and Food Intake After a Glucose Drink in Normal Weight, Overweight and Obese Boys

Conditions
-----------------
Obesity Prevention

Intervention / Treatment
-----------------
* Other: Dietary Supplement: water with noncalorie sweetener
* Other: Activity: With noncalorie sweetener or glucose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy boys with no emotional, behavioral or learning problems Exclusion Criteria: Girls

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sedentary activity, noncaloric beverage<br> | Other: Dietary Supplement: water with noncalorie sweetener<br> <br> |
| Experimental: Sedentary activity, glucose beverage<br> | Other: Dietary Supplement: water with noncalorie sweetener<br> <br> |
| Experimental: Exercise activity, noncaloric beverage<br> | Other: Activity: With noncalorie sweetener or glucose<br> <br> |
| Experimental: Exercise activity, glucose beverage<br> | Other: Activity: With noncalorie sweetener or glucose<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| food intake (kcal) |  | at 30-35 min after the treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective appetite |  | 0-80 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
boys, obesity, physical activity, exercise
Effect of Inhalation Sedation Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome Course

Study Overview
=================
Brief Summary
-----------------
Investigation of effect of inhalation sedation by administration of Sevoflurane compared with Propofol on the moderate acute respiratory distress syndrome course in mechanically ventilated patients with sepsis.

Official Title
-----------------
Effect of Inhalation Sedation With Sevoflurane Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome (ARDS) Course.

Conditions
-----------------
ARDS

Intervention / Treatment
-----------------
* Drug: Inhalation Sedation
* Drug: Intravenous Sedation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sepsis ARDS P/F Ratio 100-250 start of mechanical ventilation Exclusion Criteria: pregnancy concomitant oncological disease prior psychological impairment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Inhalation sedation<br> | Drug: Inhalation Sedation<br>* Inhalation Sedation by Administration of Sevoflurane<br>|
| Active Comparator: Propofol<br> | Drug: Intravenous Sedation<br>* Intravenous Sedation by Administration of Propofol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality | 28 days and in-hospital mortality | 28 days after ICU admission | 
| ICU Length of stay (LOS) | Length of stay in ICU | 45 days after ICU admission | 
| Length of mechanical ventilation (LMV) | Length of mechanical ventilation | 45 days after ICU admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| P/F Ratio | minimal pO2/FiO2 | 45 days after ICU admission | 
| Delirium | onset and duration of delirium | 5 days after ICU admission | 
| MACCE | Major Adverse Cardiac and Cerebrovascular Event | 28 days after ICU admission | 
| event of RRT | event of Renal Replacement Therapy | 28 days after ICU admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sedation, ARDS, sepsis, outcome
Lingual Muscle Training in Late-Onset Pompe Disease (LOPD)

Study Overview
=================
Brief Summary
-----------------
This study is being done to test the effects of Lingual Muscle Therapy (LMT) in patients with Late-Onset Pompe Disease (LOPD) who have tongue weakness. The results of this study will help design future research studies about LMT in LOPD.

Official Title
-----------------
Lingual Muscle Training in Late-Onset Pompe Disease (LOPD)

Conditions
-----------------
Glycogen Storage Disease

Intervention / Treatment
-----------------
* Other: Lingual Muscle Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Age ≥ 12 years Lingual weakness as measured by quantitative muscle testing (≤ 5% lower limit of normal for stratified age) Confirmed diagnosis of LOPD On enzyme replacement therapy for ≥ 26 weeks at pretest Able to follow directions for study participation Able to complete a home-based LMT regimen Access to reliable internet connection Access to use of electronic device that allows for FaceTime, Jabber, or WebEx use Exclusion Criteria: Neurodegenerative conditions (e.g. stroke, dementia) or other serious neurologic condition that would prevent meaningful study participation as determined at the discretion of the principle investigator Any current or past history of seizures. Head and neck cancer or radiation treatment to head/neck Inability to tolerate IOPI device tongue bulb Inability to give legally effective consent Inability to read and understand English

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Late Onset Pompe Disease who have tongue weakness<br> | Other: Lingual Muscle Training<br>* Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of lingual muscle training | Safety measured by pain rating scale | 13 weeks | 
| Feasibility of lingual muscle training as measured by questionnaires |  | 13 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in lingual strength | Change from pre-test to post-test | baseline, 13 weeks |
Increasing Bone Density by Application of Surface Electrical Stimulation

Study Overview
=================
Brief Summary
-----------------
Bonestim system for osteoporosis treatment uses surface electrical stimulation of neuromuscular and skeletal tissue by multipad stimulation electrodes for inducing contractions of the spinal column muscles. The primary aim of this clinical study is to determine if the Bonestim therapy can improve bone density. A secondary aim is to determine whether the applied treatment increases postural stability and facilitation of daily life activities. Inducing of contractions of the spinal column muscles in this manner could be new treatment options for the patients with reduced mobility and the patients with serious contraindications for drugs.

Official Title
-----------------
Increasing Bone Density by Application of Surface Electrical Stimulation

Conditions
-----------------
Osteoporosis, Electrical Stimulation, Posture

Intervention / Treatment
-----------------
* Device: Bonestim


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: T score at least 1,5 (ideal 2,-2,5) Stable bone turn over (lab.analyses.) Exclusion Criteria: fracture,pace maker, malignancy and gastrointestinal problems chronic corticosteroid therapy spinal surgery in previous year
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group treated with Bonestim<br>The experimental group will be treated with the electrical stimulation device Bonestim. | Device: Bonestim<br>* Bonestim is the multipad electrical stimulation device.<br>* Other names: multipad electrical stimulation of trunk muscles;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| density of bone measured by central Dxa measurement |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sagittal flexibility measured by Schober measurement |  | 6 months | 
| daily activities measured by Oswestry disability index |  | 6 months |
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist

Study Overview
=================
Brief Summary
-----------------
Delinieation of GIP's effects during an oral glucose tolerance test (OGTT) in humans using GIP receptor antagonisation.

Detailed Description
-----------------
Aim: To evaluate the role of GIPR signalling in postprandial physiology, including bone and glucose homeostasis, using a naturally occurring GIP fragment (GIP-A), which antagonises the GIPR. Eighteen healthy men (age 18-70 years, BMI 19-35 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin[9-39], C) GIP-A + Exendin[9-39], or D) saline (placebo).

Official Title
-----------------
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3)

Conditions
-----------------
Glucose Metabolism Disorders

Intervention / Treatment
-----------------
* Other: GIP-A
* Other: GLP-1 receptor antagonist Exendin[9-39]
* Other: Placebo
* Other: GIP-A + Exendin[9-39]


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal kidney function, liver function and hemoglobin levels. Exclusion Criteria: Medication, Diabetes type 1 or 2, first degree relatives with Diabetes type 2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Saline | Other: Placebo<br>* Saline (9mg/mL)<br>* Other names: Saline;|
| Other: GIP-A<br>Infusion of GIP-A alone as study tool. | Other: GIP-A<br>* GIP-A (GIP receptor antagonist)<br>|
| Other: GLP-1 receptor antagonist Exendin[9-39]<br>Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool. | Other: GLP-1 receptor antagonist Exendin[9-39]<br>* Exendin[9-39]<br>* Other names: EX(9-39);|
| Other: GIP-A + Exendin[9-39]<br>Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools. | Other: GIP-A + Exendin[9-39]<br>* GIP receptor antagonist + GLP-1 receptor antagonist<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin levels | Serum insulin AUC (area under the curve) | 240 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GIP, GIP receptor antagonist
Chemotherapy w/wo WeiLeShu in Metastatic Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
A total of 50 patients with metastatic colorectal cancer will be enrolled in the study. The patients were randomly divided into the WLS-intervention group and the control group. The two groups of patients were given the most appropriate medication according to the specific conditions of the disease. Patients in the intervention group received additional oral administration of Weileshu, a probiotics product (Tongchuang Biotechnology).

Official Title
-----------------
A Study of Chemotherapy With WeiLeShu Versus Chemotherapy Alone in Patients With Metastatic Colorectal Cancer

Conditions
-----------------
Microbial Colonization, Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: Weileshu
* Drug: Chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age, of any race or sex who are eligible to sign written consent and have undergone prior resection of histological evidence of colorectal cancer Hematologic function: ANC ≥ 1.5 x 10 /L, platelets ≥ 75 x 10 /L, and hemoglobin > 9 g/dL Adequate liver function as measured by: total bilirubin ≤ 2.0 mg/dl, AST and ALT ≤ 5 ULN, albumin ≥ 2.5 g/dl Adequate renal function as measured by: creatinine ≤ 2.9 mg/dl, > 50 ml/min calculated by the C-G equation Non-pregnant women of childbearing potential and fertile men are required to use effective contraception (negative pregnancy test for women of child-bearing age) ECOG status ≤ 1 at screening Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: WLS-intervention group<br>chemotherapy + WLS | Drug: Weileshu<br>* a probiotics products which help to rebuild homeostasis of gut microbiome<br>Drug: Chemotherapy<br>* chemotherapy<br>|
| Active Comparator: the control group<br>chemotherapy | Drug: Chemotherapy<br>* chemotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival | time from randomization to progression | up to approximately half a year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival | time from randomization to death | up to approximately two years |